Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Summary
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum.
This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.
Study Design
Control: Active Control, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Pyoderma Gangrenosum
Intervention
Infliximab
Location
University Hospitals Case Medical Center
Cleveland
Ohio
United States
44106
Status
Completed
Source
University Hospital Case Medical Center
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00791557
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Pyoderma Gangrenosum
An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.
Pyoderma
Any purulent skin disease (Dorland, 27th ed).
Ecthyma
An ulcerative pyoderma usually caused by group A beta-hemolytic streptococcal infection at the site of minor trauma. (Dorland, 27th ed)
Pyomyositis
An intramuscular suppuration of the large skeletal muscle groups. It is associated with INFECTION such as STAPHYLOCOCCUS AUREUS and PYODERMA. It was known as a tropical disease but is increasing among the immunocompromised (IMMUNOCOMPROMISED HOST). Symptoms include muscle pain, FEVER, and leucocytosis. It has been diagnosed by MRI SCANS.
Clinical Trials
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.
Prevalence of RHD, Pyoderma and Scabies in Children in Fiji
The purpose of this study is to estimate the number of cases of rheumatic heart disease, pyoderma, and scabies in school age children in Fiji. In addition the study will describe the featu...
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Patients from an ongoing observational study (P05319) who have a limited (adequate but less than optimal) response to infliximab will be randomized to either increase the frequency of infl...
To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to cur...
PubMed Articles
Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG...
Pyoderma gangrenosum is a rare ulcerative disorder of the skin of unknown etiology. We present a case of pyoderma gangrenosum that occurred following total knee arthroplasty, which was initially misdi...
Sunitinib Induced Pyoderma Gangrenosum-like Ulcerations.
Pyoderma gangrenosum is a non-infectious neutro?philic skin disease commonly associated with underlying systemic diseases. Histopathological and laboratory diagnostics are unspecific in the majority o...
Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study.
Oral phenytoin is an extensively used medicine for the treatment of convulsive disorders. Topical phenytoin has also been used for various types of ulcers. To determine the effectiveness of 2% topical...
Pyoderma gangrenosum is a rare autoinflammatory syndrome manifested by skin lesions eventually creating ulcers. Surgical management can lead to scarring and contracture at the site of the lesion due t...
